Clinical Trial Update: Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vicriviroc added to optimized antiretroviral therapy for HIV/ AIDS was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infections

Drugs mentioned

• Vicriviroc (MK-7690)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections, Acquired Immunodeficiency Syndrome | Phase 3 | Status: WITHDRAWN